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Abstract
Background: Plasmodium vivax is one of the major species of malaria infecting humans. Although emphasis on P.
falciparum is appropriate, the burden of vivax malaria should be given due attention. This study aimed to synthesize the
evidence on severe malaria in P. vivax infection compared with that in P. falciparum infection.
Methods/Principal Findings: We searched relevant studies in electronic databases. The main outcomes required for
inclusion in the review were mortality, severe malaria (SM) and severe anaemia (SA). The methodological quality of the
included studies was assessed using the Newcastle-Ottawa Scale. Overall, 26 studies were included. The main meta-analysis
was restricted to the high quality studies. Eight studies (n = 27490) compared the incidence of SM between P. vivax infection
and P. falciparum mono-infection; a comparable incidence was found in infants (OR: 0.45, 95% CI:0.04–5.68, I2:98%), under 5
year age group (OR: 2.06, 95% CI: 0.83–5.1, I2:83%), the 5–15 year-age group (OR: 0.6, 95% CI: 0.31–1.16, I2:81%) and adults
(OR: 0.83, 95% CI: 0.67–1.03, I2:25%). Six studies reported the incidences of SA in P. vivax infection and P. falciparum mono-
infection; a comparable incidence of SA was found among infants (OR: 3.47, 95%:0.64–18.94, I2: 92%), the 5–15 year-age
group (OR:0.71, 95% CI: 0.06–8.57, I2:82%). This was significantly lower in adults (OR:0.75, 95% CI: 0.62–0.92, I2:0%). Five
studies (n = 71079) compared the mortality rate between vivax malaria and falciparum malaria. A lower rate of mortality was
found in infants with vivax malaria (OR:0.61, 95% CI:0.5–0.76, I2:0%), while this was comparable in the 5–15 year- age group
(OR: 0.43, 95% CI:0.06–2.91, I2:84%) and the children of unspecified-age group (OR: 0.77, 95% CI:0.59–1.01, I2:0%).
Conclusion: Overall, the present analysis identified that the incidence of SM in patients infected with P. vivax was
considerable, indicating that P. vivax is a major cause of SM. Awareness of the clinical manifestations of vivax malaria should
prompt early detection. Subsequent treatment and monitoring of complications can be life-saving.
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Introduction
Plasmodium falciparum and P. vivax are the two major species
of malaria infecting humans. Although emphasis on P. falciparum
is appropriate, the burden of vivax malaria should be given due
attention as almost 40% of the world population are at risk of
vivax malaria [1]. Historical evidence from the neurosyphilis
therapies in the early 1900s showed 5–15% fatality rates in the
American and European treatment facilities using P. vivax,
indicating that P. vivax is dangerous and not benign [2]. P. vivax
malaria is prevalent in many regions of the world, and in Asia and
Latin America it accounts for more than half of all the malaria
cases [3,4]. In 2009, it was reported that 2.85 billion people were
at risk of P. vivax transmission and 91% of these occurred in
Central and South East Asia [5].
Recently, there has been a surge in studies that reported the
contribution of P. vivax to severe malaria (SM) in countries such
as Thailand [6], Brazil [7], Indonesia [8], Papua New Guinea
(PNG) [9] and India [10]. It has been well documented that severe
anaemia (SA), a presenting clinical manifestation of SM, is an
important determinant of infant mortality [11] in endemic areas.
The incidence of clinical manifestations of severe vivax malaria
has been reported from endemic areas, albeit with variations in the
presenting clinical patterns. Individual studies assessing the
prevalence of SM related to vivax malaria are available, but their
findings are inconclusive. Reviews addressing studies in the
Brazilian context only [12] and a review on SA alone [11] were
available. To our knowledge, no statistical pooling of results has
been undertaken. This gap in evidence stimulated us to conduct a
systematic review and meta-analysis. Meta-analysis is the process
of combining study results that can be used to draw conclusions.
The final product has both quantitative and qualitative elements,
as it takes into account the numerical results and sample sizes of
the individual studies as well as the more subjective issues such as
quality, extent of bias, and strength of the study design [13].
Therefore, the objective of the present study was to synthesize
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evidence on SM in P. vivax infection compared with that in P.
falciparum infection.
Methods
The present study followed the preferred reporting items for
systematic reviews and meta-analyses (PRISMA) statements [14]
(Checklist S1).
Study search
We searched studies on the relative distribution of severe
malaria in a P. vivax infection in electronic databases such as
PubMed, Ovid and Google Scholar. The search was limited to
studies published in English until February 2014. We used the
following medical subject heading (MeSH) and/or text words in
any field, ‘‘(vivax malaria OR vivax)’’ combined with ‘‘(severe
malaria OR complicated malaria OR severe anaemia OR severe
malaria anaemia).’’ The search strategy was slightly modified
according to the requirements of different databases. We also
looked at the references of retrieved articles and relevant reviews
for any additional studies.
Study selection
Studies were selected for the present meta-analysis if they met
the following criteria:
Study population. Participants residing in malaria endemic
countries presenting with clinical manifestations of P. vivax
infection, regardless of age and gender. Microbiological diagnosis
of malaria was made based on microscopy of Giemsa-stained
blood films or a rapid-onsite diagnostic test and with species
confirmation through PCR-based analysis.
Study design. Observational designs, prospective cohort and
case-control designs (case-control/nested-case control studies
carried out with a clear description of the selection of controls)
were considered. Studies which compared SM between P. vivax
and P. falciparum (either mono-infection or mixed infection),
and/or compared patients with SM and non-SM in P. vivax
malaria were included.
Study outcomes. The outcomes were SM, SA, and other
common clinical manifestations related to vivax malaria. SM for
P. vivax was defined according to standard criteria of the World
Health Organization (WHO) for P. falciparum [15] with the
exception of the criterion for parasite density. This is because P.
vivax preferential invasion of younger red blood cells (reticulo-
cytes) necessarily lowers the threshold at which it would be
considered to be hyperparasitaemic. SA was defined as having
haemoglobin levels of ,7 g/dL in adults and ,5 g/dL in
children, according to the WHO criteria [15,16]. For the outcome
assessment, studies which provided relative risk (RR) or odds ratio
(OR) estimates with its 95% confidence interval (95% CI) (or data
to calculate the estimates) were included. If more than one study
presented data from the same study participants, either the study
of the higher quality or the most comprehensive was included.
Studies were excluded from the meta-analysis, if they (i) were
case reports, (ii) assessed particular populations (e.g. non-immune
travelers, pregnant mothers, patients with known co-morbid
conditions), (iii) had a sample size less than 10, (iv) had measured
outcomes which were not clearly presented, or (v) were studies
from which appropriate data could not be extracted.
Data extraction
Two authors independently screened the titles and abstracts of
publications according to the inclusion criteria. These two authors
then independently extracted information from each of the
included studies using the pre-tested data extraction form
prepared for this study. Information collected was author, year
of publication, country, patient characteristics, sample size, mean
age, gender, study design and the reported clinical outcomes.
Disagreements between the two authors were resolved by
consensus. The methodological quality of the included studies
was assessed using the Newcastle-Ottawa Scale (NOS) [17]. The
instrument used a star system to assess the study quality based on
three criteria; (i) participants’ selection (4 stars), (ii) comparability
of study groups (2 stars) and (iii) assessment of exposure (3 stars).
Hence, the highest total score for a study was nine.
Data analyses
We assumed that the RR from cohort studies approximates OR
from case-control studies [18]. In order to assess the differences
between the various clinical manifestations of P. vivax and P.
falciparum infections (either mono or mixed), we extracted
adjusted OR and corresponding 95% CI from each study,
wherever possible. If RR or OR was not reported, we calculated
these from the raw data provided in the study. As the incidence of
SM is not very high, a more conservative estimate of the OR was
used for the pooled analysis. The heterogeneity between these
studies was assessed with the I2 test. A calculated value of I2 over
50% indicated substantial heterogeneity. For pooling of the results,
we used a more conservative random-effect model [19]. This is
because even if the I2 statistic is low or zero, heterogeneity could
still be a concern since it is likely to be present but undetected [20].
The measure of effect sizes is the OR, but statistical analysis was
carried out with its natural logarithm (i.e the log OR) since a
sampling distribution is more closely approximated by a normal
distribution [21]. Moreover, we thought that some of the included
studies might have been poorly conducted or poorly reported. This
makes the reliability of their input data questionable. Therefore,
we performed meta-analyses restricted to the high quality studies
(i.e. studies with ,7 score). The remaining relatively low quality
studies were retained for a sensitivity analysis.
Author Summary
Until recently, vivax malaria has received less attention
than falciparum malaria and was deemed neglected. There
has been a surge in studies that documented the
contribution of Plasmodium vivax to severe malaria in
some endemic countries such as Thailand, Brazil, Indone-
sia, Papua New Guinea and India. We aimed to synthesize
the evidence on severe malaria in P. vivax infection
compared with that in P. falciparum infection. We searched
relevant studies in electronic databases. The combined
results of the eight relatively high quality studies showed a
comparable incidence between vivax malaria and falci-
parum malaria in infants, under 5 year age group, the 5–15
year age group and adults. The combined results of the six
relatively high quality studies revealed a comparable
incidence of severe anaemia between P. vivax infection
and P. falciparum mono-infection in both the infants and
the 5–15 year age group. Considering that severe malaria
and deaths attributable to P. vivax is not a rare event,
raised clinical awareness of the manifestations of vivax
malaria in patients of any age should prompt early
detection of malaria. It is likely that early detection,
appropriate treatment commenced in a timely manner
and close monitoring of any complications could be life-
saving and contribute to the attainment of the global
vision of no malaria deaths.
Severe Vivax Malaria: Systematic Review and Meta-Analysis
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If data allowed, we stratified the incidence of SM by age groups
(infants, under 5 years, 5–15 years), by transmission intensity (with
or without marked seasonality), by species (P. vivax, P. falciparum
and mixed infections) and by chloroquine (CQ) resistance status.
The presence of publication bias was assessed by visualizing funnel
plots. Data entry and analyses were performed using RevMan
(version 5.3) (The Cochrane Collaboration, Nordic Cochrane
Centre, Copenhagen, Denmark). A protocol of this study is
available [22].
Results
Figure 1 presents the study selection process. The initial search
yielded 750 citations, of which 39 potentially met the inclusion
criteria. Of them, 26 studies were identified for consideration
in quantitative synthesis [8,10,23–46]. Thirteen studies were
excluded because (i) there was no comparator group [3,47–50],
(ii) there were no data on SM cases [51–54], (iii) there were no
data on P.vivax infection [55], (iv) they were review articles [7,56]
and (v) they were studies of a particular population (i.e military
group) [57].
Baseline characteristics of the included studies
Table S1 presents the characteristics of the included studies.
Many studies were conducted in India (n = 10) [10,28,
31,32,34,35,37,42,44,45], Indonesia (n = 5) [8,26,27,40,41]. The
remaining studies came from Pakistan (n = 3) [30,43,46], PNG
(n = 3) [29,38,39], Brazil (n = 2) [24,36], Ethiopia (n = 1) [33],
Malaysia (n = 1) [25] and Sudan (n = 1) [23]. Ten studies (38.4%)
were published in the year 2013. Also, 38.4% of the included
studies confirmed vivax malaria by PCR. Of the 26 included
Figure 1. Flow diagram indicating the study selection.
doi:10.1371/journal.pntd.0003071.g001
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studies, only 10 studies (38.4%) were high quality studies ($7
scores), on the basis of the NOS checklist in which the maximum
score is 9 (Table S2). We only considered high quality studies for
the main meta-analyses. The remaining studies with lower quality
scores were retained for sensitivity analysis.
Some studies were low in their quality because the ‘follow-up
period’ was not long enough (or failed to report this duration) for
outcomes to have occurred [10,23,28,30,37,41,42,44]. Some
studies failed to address the assessment of ‘common outcomes’
[10,28,30,35,37,41,42,44,45]. Failure to address any of these
important criteria could affect the validity of their study process
and/or outcome measurements.
Mortality attributable to vivax malaria
Of the 26 included studies, 8 studies (n = 74079)
[8,10,26,27,34,37,40,43,46] reported the percentage of mortality
attributable to P. vivax. Compared with P. falciparum malaria,
the mortality rate among infants was significantly lower in P. vivax
infection (summary OR: 0.61, 95% CI: 0.5–0.76, I2: 0%). But, the
mortality rate between vivax and falciparum malaria was
comparable in under 5 year-age –group (summary OR: 0.43,
95% CI: 0.06–2.91, I2: 84%) (Figure 2).
Five studies (n = 33824) [8,26,27,34,40] reported the percentage
of mortality, comparing P. vivax infection with mixed infection (P.
falciparum and P. vivax); the mortality rates among infants
(summary OR: 0.79, 95% CI: 0.58–1.08, I2: 0%) and among
children in the 5–15 year-age group (summary OR: 0.66, 95% CI:
0.12–3.74, I2: 0%) were comparable (Figure S1).
Severe malaria
Eight studies (n = 27490) [8,25,26,29,32,34,38,40] were includ-
ed in the pooled analysis. A comparable incidence of SM between
P. vivax infection and P. falciparum mono-infection was found in
infants (summary OR: 0.45, 95% CI: 0.04–5.68, I2:98%), under 5
year-age group (summary OR: 2.06, 95% CI: 0.93–5.1, I2:83%),
the 5–15 year-age group (summary OR: 0.61, 95% CI: 0.31–1.16,
I2:81%), children of any age (summary OR: 0.94, 95% CI: 0.2–
4.36, I2:99%) as well as in adults (summary OR: 0.83, 95% CI:
0.67–1.03, I2:25%) (Figure 3).
Five studies (n = 3064) [8,29,34,38,40] compared the incidence
of SM between P. vivax malaria and mixed infection and reported
a significantly lower incidence among 5–15 year- age group
(summary OR: 0.2, 95% CI: 0.05–0.79, I2: 89%) and comparable
incidence among infants (summary OR: 0.34, 95% CI: 0.05–2.57,
I2: 96%) (Figure S2).
Severe anaemia
Six studies [8,25–27,34,40] which compared the incidences of
SA between P. vivax infection and P. falciparum mono-infection
were included in the pooled analysis. A comparable incidence of
SA between P.vivax infection and P. falciparum mono-infection
was found in infants (summary OR: 3.47, 95%CI: 0.64–18.94, I2:
92%) as well as in the 5–15 year-age group (summary OR: 0.71,
95%CI: 0.06–8.57, I2: 82%). Of note, there is substantial between-
study heterogeneity. This estimate, however, was significantly
lower in adults (summary OR:0.75, 95%CI: 0.62–0.92, I2: 0%)
(Figure 4). A pooled analysis of 2 studies [8,34] showed a
comparable incidence of SA between P. vivax infection and
mixed infection (P. falciparum and P. vivax) in under 5 year-age-
group (summary OR: 2.57, 95% CI: 0.12–56.44, I2:87%) as well
as in the 5–15 year-age group (summary OR: 2.39, 95% CI: 0.94–
6.09, I2:40%) (Figure S3). Two studies [24,26] compared
incidence of SA between severe and non-severe (uncomplicated)
vivax malaria; there was a 6-fold increase in incidence of SA in the
Figure 2. Forest plot showing a comparison of mortality between P. vivax and P. falciparum mono-infections.
doi:10.1371/journal.pntd.0003071.g002
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group of severe vivax malaria (summary OR: 6.1; 1.92–19.39, I2:
0%) (Figure S4).
Acute respiratory distress in severe vivax malaria
Three studies [8,25,26] reported higher incidence of acute
respiratory distress (ARD) in P. vivax infection compared to P.
falciparum mono or mixed infection. Two studies on adult
participants [8,25] reported a lower incidence of ARD in P. vivax
infection compared to P. falciparum mono-infection (summary
OR: 0.31, 95% CI: 0.17–0.58, I2: 0%), whilst 2 studies on children
of any age (i.e unspecified age group) [8,26] showed a comparable
incidence of ARD between P. vivax and P. falciparum infections
(summary OR: 1.79, 95% CI: 0.23–14.19, I2:61%) (data not
shown). Only one study [8] provided data on ARD amongst adult
participants, showing a significantly lower incidence of ARD in P.
vivax infection compared with mixed infection (OR: 0.44, 95%
CI: 0.2–0.96).
Cerebral malaria
One study on adult participants [10] reported a lower incidence
of cerebral malaria in P.vivax infection than in P. falciparum
mono-infection (OR: 0.53, 95% CI: 0.32–0.87). However, two
studies on children (n = 229) [34,45] showed a comparable
incidence of cerebral malaria between P. vivax and P. falciparum
infections (summary OR: 0.47; 95%CI: 0.12–1.2, I2: 0%) (Figure
S5).
Figure 3. Forest plot showing a comparison of severe malaria between P. vivax and P. falciparum mono-infections.
doi:10.1371/journal.pntd.0003071.g003
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Subgroup analysis and sensitivity analysis
Based on available data, we stratified the included studies on
SM in the 5–15 year-old children into those which carried out in
the study sites where CQ resistance is believed to pay a major role
and those with study sites where CQ resistance is not a problem.
In both subgroups, a comparable incidence of SM was found
between P. falciparum infection and P.vivax infection (CQ
resistant sites: summary OR: 0.42, 95% CI: 0.17–1.06, I2:93%
and not CQ resistant sites: summary OR: 0.58, 95% CI: 0.32–
1.05, I2:69%) (Figure 5). Notably, statistical heterogeneity was
relatively lower with higher effect estimates and narrower CI
among studies in which CQ resistance was not a major problem.
A sensitivity analysis including relatively low quality studies
showed a significantly lower incidence of SM in P. vivax infection
than in P. falciparum infection amongst the 5–15 year-age group
(summary OR: 0.45, 95% CI: 0.25–0.81, I2:91%) (Figure S6).
Hence, the methodological quality of studies included could have
influenced the combined estimates. Compared to P.falciparum
infection, the 5–15 year-age group with P.vivax infection have
comparable incidence of SA (summary OR:1.43, 95% CI:0.38–
5.35, I2:79%) (data not shown). An inspection of the funnel plot
asymmetry showed a possible publication bias among studies on
SM (Figure 6).
Discussion
Overall, the present analysis identified that the incidence of SM
in P. vivax infection was considerable, indicating that P. vivax
infection could be a major cause of SM.
Seriousness of vivax malaria
Dating back to the era of induced malaria therapy, the fatality
rate with the Madagascar strain of P. vivax, which is a notoriously
virulent strain with relatively good efficacy against neurosyphilis
was 10–15% for patients in the United Kingdom [58]. A detail of
this evidence is available elsewhere [2]. In fact, vivax malaria is
never ever rare and benign [47,59]. The fact that P. vivax has a
higher chance of fatality is supported by a study on autopsy case
series in Latin America, in which 13 of 17 post-mortem
characterization of deceased patients have confirmation of P.
vivax infections [60].
There are several possible explanations for this observation of
severe vivax malaria. A long-lasting liver stage of P. vivax allows
Figure 4. Forest plot showing a comparison of severe anaemia between P. vivax and P. falciparum infections.
doi:10.1371/journal.pntd.0003071.g004
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prolonged periods for the parasite to remain in a host population,
even if transmission is interrupted and the primary infection has
been treated successfully [61]. It might also be related to recurrent
infections resulted from treatment failure of P. vivax [8,29].
Failure to attack the hypnozoite reservoir in patients causes a
single infectious bite by a mosquito to result in repeated attacks
and opportunities for further transmission [2]. The most frequent
malaria related complications reported from P. vivax endemic
countries are SA and ARD [8,31,33,37]. This pattern was also
demonstrated in the current pooled analysis. In settings where
malaria is endemic, inadequate therapy and repeated relapses are
the primary instruments of severe morbidity and mortality in vivax
malaria [2]. Overall, mortality was lower in vivax malaria than in
falciparum malaria in certain age groups. Although pathophysi-
ology of vivax malaria is not fully understood, the inability of
infected red blood cells (RBCs) to adhere to vascular endothelium
and the parasite’s strict preference for invading reticulocytes could
explain the widely accepted ‘nonaggressive course’ of vivax
malaria [61].
Severe anaemia as a presentation of severe vivax malaria
Findings of the current review highlighted that vivax malaria is
related to SM, in which SA is a relatively common clinical
manifestation. It has been well established that the primary target
of human plasmodium species is the RBCs [11]. Mechanisms
similar to those operating in the SA of P. falciparum could have
contributed to the anaemia or there may be different pathways.
P.vivax has a very strong predilection for RBCs, particularly
reticulocytes, whereas P. falciparum has only a moderate
predilection [11]. Like in P. falciparum, the continued presence
of vivax parasites may have been sufficient to infect and destroy
most of the new reticulocytes, thereby hindering the timely
restoration of the erythrocytes population [62] and this could
(partly) lead to extreme anaemia over a period of several months
[11]. Moreover, there could have been compounding factors like
the impaired immune response of P. vivax-infected patients as a
result of recrudescence, reinfection, and relapse [63].
Cerebral malaria and ARD as presentations of severe
vivax malaria
The lack of rigidity of infected RBCs in vivax malaria makes the
blockage of capillary beds in internal organs unlikely. Thus, the
frequency of severe organ-specific clinical manifestations is lower
in P. vivax infection compared to P. falciparum infections [63].
This may be the reason cerebral malaria in adults was less
frequently reported in the included primary studies of the present
review. A comparable incidence of cerebral malaria between these
two infections amongst children found in this review may likely be
related to lower immunity level in children than in adults.
Published studies had shown that compared to other unusual
complications of P. vivax infection, cerebral malaria is relatively
rare, but when it occurs it is associated with high mortality [63].
Hence, more attention and support should be given to the
investigation of P. vivax infections in regions such as Indian
Figure 5. Stratified analysis of severe malaria according to the chloroquine resistant status of the study sites.
doi:10.1371/journal.pntd.0003071.g005
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subcontinent [47]. The presumed pathogenesis of central nervous
system malaria is postulated to involve adherence of parasitized
RBCs to the cerebral vascular endothelium ultimately impeding
the cerebral blood flow [47]. Further production of TNF and
subsequent cytokine imbalance are likely to play a role.
Our findings reinforce the finding of individual studies
[39,40,44] as well as a review on vivax malaria in Brazil [12]
that vivax malaria’s clinical manifestations such as ARD and
death, are comparable in severity to those caused by P.
falciparum. The lower frequency of ARDS in vivax malaria may
be related to the absence of microvascular sequestration of infected
RBC [64–66], less tissue localization of plasmodium toxin release,
resulting in lower degree of microvascular inflammatory response
and ischemia-reperfusion injury [65]. Indeed, the pathogenesis of
SM is incompletely understood and establishing the causal role of
any single mechanism in SM in humans [67] is rather complex.
The detailed information on the pathophysiology of vivax malaria
is beyond the scope of the current study. Comprehensive
information on pathophysiology of vivax malaria pertinent to SA
is available elsewhere [11].
Age-specific severe vivax malaria
Published studies reported that the distribution of SM was age-
specific [27,29]. This is indirectly supported by the current
analysis. SA was found to be more frequent in the group of infants
infected with P. vivax. It has been postulated that a greater risk of
SA in early life (infants in this case) could be partly explained by a
relatively faster acquisition of immunity in P. vivax compared with
that in P. falciparum [29,51,65]. Infancy is a time of rapid physical
and cognitive development as well as increased vulnerability to
infectious disease. The risk of SA is, therefore, more heavily
skewed towards infancy and faster acquisition of immunity [27] in
this group of population. A lower incidence of SM in P.vivax
infection compared with that in mixed infection among the 5–15
year-old children could also be related to the seemingly uniform
lower prevalence of vivax malaria in endemic areas. This could
partly be attributed to the parasite density.
Points on diagnosis of severe vivax malaria
The WHO severity criteria formerly only validated for P.
falciparum infection seems to be applicable to most of the P. vivax
patients admitted to the intensive care unit (ICU) as at least one of
these severity criteria was present in most of the patients admitted
[36]. However, definitive criteria for severe disease for P. vivax are
not validated and the adoption of the WHO thresholds for disease
severity for another species needs to be reassessed. For instance,
severe disease with P. falciparum infection is considered with
parasitaemia .200,000/mL, while parasitaemia exceeding
50,000/mL is rare in severe malaria with P. vivax [43]. In one
study parasitaemia .500/uL was associated with hospitalization
in the ICU [36]. Vivax malaria is a potentially life threatening
infection despite relatively low-grade parasitaemia in peripheral
Figure 6. Funnel plot showing publication bias among studies on severe malaria.
doi:10.1371/journal.pntd.0003071.g006
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blood [2]. P. vivax infections have lower parasite biomass
compared with P. falciparum malaria patients of the given age.
P. vivax has a tendency to achieve and maintain lower density
parasitaemia, and the inverse relationship between diagnostic
sensitivity and parasitaemia count [61]. This is because the
preferential invasion of younger RBCs (reticulocytes) by P.vivax
lowers the threshold at which it would be considered to be
hyperparasitaemic. Another hypothesis is that vivax malaria may
be primarily an infection of haemopoetic tissues rather than the
vascular sinus. Thus, a biomass of P. vivax exterior to the vascular
sinus could expand dangerously without detection [2].
Impact of chloroquine resistance
Geographical areas that reported severe vivax malaria are the
same that demonstrated P. vivax CQ resistance [60]. The
subgroup analysis, based on the CQ sensitivity status in the study
sites has indicated that SM was comparable between vivax malaria
and falciparum malaria in both sites, regardless of CQ sensitivity
pattern. However, relatively lower statistical heterogeneity and
slightly higher effect estimates with narrower CI among the studies
sites such as East Sepik Province of PNG where CQ resistance is
not a major problem or no problem [29]. This implies that the CQ
sensitivity pattern reported from the study sites could have
influenced the combined estimates. It is important to note the
genesis of recommended therapy which constitutes a critical factor
for CQ resistance. CQ was commenced as the first line therapy for
P.vivax in 1946. Although as little as 0.3 gram CQ routinely cured
CQ sensitive P. vivax, the treatment protocol made no distinction
between P. vivax and P. falciparum for the recommended 1.5
gram total adult dose for treating acute attacks of malaria. This
might, in part, explain the relatively late first known appearance of
CQ resistant P. vivax in 1989 from PNG [68]. Studies have shown
that both single nucleotide polymorphism and amplification of
pvmdr1 gene are related to variation in the in vitro susceptibility of
P. vivax similar to pfmdr1 in P. falciparum [68,69]. When there is
a drug resistance trait in a certain area, recurrent infections due to
failure to eliminate the parasites early in infection and subsequent
relapse from the liver stages [8] resulted in an increased peripheral
parasitaemia for a longer time, enhancing haemolysis of RBCs
[33] and the subsequent development of SA. Moreover, when
compounded by poor immunity, CQ resistant parasites have a
greater potential to result in more severe disease, although further
studies are needed to confirm this [8]. Confirmation would require
evidence of adequate compliance to and absorption of therapy
under reliable supervision or, ideally, by determination of the
levels of drug (CQ in this case) in the blood. An outstanding
research issue related to vivax malaria is addressing the effective
alternative therapies for CQ-resistant strains [68].
Study limitations
Co-infection with other endemic infectious agents could not be
ruled out among the participants in the included studies. For
instance, a study in Pakistan reported that 12% of patients with
vivax malaria had co-existing infection [46]. Hence, there is likely
to be an ascertainment bias in the diagnosis of malaria. It is more
noticeable in areas of unstable transmission where older adults
suffering from chronic conditions such as hypertension, diabetes,
or cirrhosis are more prone to develop malarial disease [60]. It was
found that age classification was not consistently reported in the
included studies. Therefore, the differences in the age groups of
participants in the included studies rendered pooled analysis
difficult to perform. For instance, the age of participants was
classified as 0–5 years including infants [29], while other was
classified it separately as infants and 1- ,5 year-old [8,27]. P.
vivax has a strong predilection for reticulocytes, which are highest
in the second postnatal month [70]. Hence, studies in which the
analysis of infants and older children are combined might lead to a
measurement bias. The present meta-analysis could have been
more robust if we had included the relevant literature in non-
English languages. Some such literature could have been missed
when English-language abstracts were not available. Despite
literature search in electronic database using the appropriate
search terms, some studies still could have been missed.
Age as a risk factor for SM could have been confounded by the
seasonality of malaria in the study settings. This was supported by
a prospective study carried out in PNG in which vivax malaria
patients attending the clinics during wet season had approximately
two times greater chance of having SM than those patients during
the dry season (OR 1.9,95% CI:1.2–2.9), while it was OR 1.1(95%
CI 0.9–1.4) for P. falciparum mono-infection and OR 0.8 (95%
CI: 0.4–1.9) for P. falciparum mixed infections [29]. The year of
attendance of patients is likely to impact on caseloads since the
implementation of new treatment policy in the study areas could
have resulted in fewer cases in post-intervention period of that year
[29]. Moreover, manifestations of SM could be influenced by
context-dependent factors. The fact that I2 value remains high
despite sensitivity analysis implies a de facto random distribution of
heterogeneity. There may be factors inherent in the included studies
such as the level of endemicity, the presence of co-infections,
accessibility to effective malaria treatment, and the development of
parasite resistance. Inadequate data preclude us from performing
stratified analyses based on all these influencing factors.
Implications
There are important implications for malaria control programmes
based on the current findings that PCR confirmed P. vivax infections
can present as severe disease. The current analysis has documented
that the two parasites may occur in equal proportions of SM. The
global malaria control strategy and action plan need to readdress the
fallacy that vivax malaria is ‘benign’ and not fatal. The vision of no
deaths from malaria and a malaria free world requires that vivax
malaria should be taken seriously; investments in prevention,
diagnosis and treatment strategies to control and eliminate vivax
malaria are critically part of achieving this aim.
Because different parasites need to be treated differently, the
ability to diagnose the clinical manifestation of vivax malaria at the
healthcare provider level must be strengthened. The subsequent
appropriate and effective treatment of vivax malaria and monitor-
ing of clinical course and complications can be life-saving. Although
the current review has provided evidence of severity of P. vivax
infection, upcoming well designed prospective studies are needed to
substantiate vivax related SM in other epidemiological settings.
Supporting Information
Figure S1 Forest plot showing a comparison of mortality
between P. vivax and P. falciparum mixed infections.
(PDF)
Figure S2 Forest plot showing a comparative incidence of severe
malaria between P. vivax and mixed infections.
(PDF)
Figure S3 Forest plot showing a comparative incidence of severe
anaemia between P. vivax and mixed infections.
(PDF)
Figure S4 Forest plot showing a comparative incidence of severe
anaemia between severe vivax and non-severe vivax malaria.
(PDF)
Severe Vivax Malaria: Systematic Review and Meta-Analysis
PLOS Neglected Tropical Diseases | www.plosntds.org 9 August 2014 | Volume 8 | Issue 8 | e3071
Figure S5 Forest plot showing a comparative incidence of
cerebral malaria between P. vivax and P. falciparum infections.
(PDF)
Figure S6 Sensitivity analysis showing a comparative incidence
of severe malaria in the 5–15 year-age group.
(PDF)
Table S1 The characteristic of the included studies.
(RTF)
Table S2 The methodological quality of the included studies.
(RTF)
Checklist S1 PRISMA checklist.
(RTF)
Acknowledgments
The authors are grateful to the participants and researchers of the primary
studies identified for the present review. We thank the anonymous
reviewers and editors for giving us the comments and helpful input to
improve the manuscript. We are grateful to the International Medical
University (IMU), Malaysia for allowing us to perform this study. CN
acknowledges the valuable advice given by Dr. Kyan Aung.
Author Contributions
Conceived and designed the experiments: JWM MAW. Performed the
experiments: CN MAW. Analyzed the data: CN MAW. Contributed
reagents/materials/analysis tools: CN MAW VNW. Contributed to the
writing of the manuscript: CN MAW. Contributed additional information:
JWM.
References
1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM (2007) Vivax
malaria:neglected and not benign. Am J Trop Med Hyg 77(6 Suppl): 79–87.
2. Baird JK (2013) Evidence and implications of mortality associated with acute
Plasmodium vivax malaria. Clin Microbiol Rev 26: 36–57.
3. Carlton JM, Sina BJ, Adams JH (2011) Why is Plasmodium vivax a neglected
tropical disease? PLoS Negl Trop Dis 5:e1160.
4. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, et al (2005)
Plasmodium vivax malaria. Emerg Infect Dis 11:132–134.
5. Guerra CA, Howes RE, Patil AP, Gething PW, et al (2010) The international
limits and population at risk of Plasmodium vivax transmission in 2009. PLoS
Negl Trop Dis 4: e774.
6. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, et al (1997) The
epidemiology of severe malaria in an area of low transmission in Thailand.
Trans R Soc Trop Med Hyg 91: 256–262.
7. Lomar AV, Vidal JE, Lomar FP, Barbas CV, Matos GJ, et al (2005) Acute
respiratory distress syndrome due to vivax malaria: case report and literature
review. Braz J Infect Dis 9: 425–430.
8. Tjitra E, Anstey NM, Sugiarto P, Wariker N, et al (2008) Multidrug-resistant
Plasmodium vivax associated with severe and fatal malaria: A prospective study
in Papua, Indonesia. PLoS Med 5:e128.
9. Price RN, Dorsey G, Nosten F (2009) Antimalarial therapies in children from
Papua New Guinea. N Engl J Med 360:1254.
10. Nadkar MY, Huchche AM, Singh R, Pazare AR (2012) Clinical profile of severe
Plasmodium vivax malaria in a tertiary care centre in Mumbai from June 2010–
January 2011. J Assoc Physicians India 60:11–13.
11. Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, et al (2012)
The anaemia of Plasmodium vivax malaria. Malar J 11:135.
12. Costa FT, Lopes SC, Albrecht L, Ataı´de R, Siqueira AM et al (2012) On the
pathogenesis of Plasmodium vivax malaria: perspectives from the Brazilian field.
Int J Parasitol 42:1099–1105.
13. L’Abbe KA, Detsky AS, O’Rourke K (1987) Meta-analysis in clinical research.
Ann Intern Med 107:224–233.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P (2009) Preferred reporting
items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS
Medicine 6; e1000097.
15. WHO (World Health Organization) (2000) Severe falciparum malaria.
Trans R Soc Trop Med Hyg 94 (Suppl 1):S1–90.
16. Moorthy VS, Reed Z, Smith PG, on behalf of the WHO group on measures of
malaria vaccine efficacy (2007) Measurement of malaria vaccine efficacy in
phase III trials: report of a WHO consultation. Vaccine 25: 5115–
5123.
17. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al (2011) The
Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised
studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. Available:
www.ohri.ca/programs/clinical_epidemiology/oxford.htm accessed 16 Febru-
ary 2014.
18. Greenland S, Thomas DC, Morgenstern H (1986) The rare-disease assumption
revisited. A critique of estimators of relative risk for case-control studies.
Am J Epidemiol 124:869–983.
19. Higgins JPT, Green S, eds. (2011) Cochrane Handbook for Systematic Reviews
of Interventions.Version 5.1.0 (updated March 2011). The Cochrane Collab-
oration; 2011. Available; www.cochranehandbook.org. Accessed 18 February
2014
20. Kontopantelis E, Springate DA, Reeves D (2013) A re-analysis of the cochrane
library data: the dangers of unobserved heterogeneity in meta-analyses. PLoS
ONE 8(7): e69930. doi:10.1371/journal.pone.0069930
21. Harbord RM, Higgins JPT (2008) Meta-regression in Stata. The Stata Journal 8:
493–510.
22. PROSPERO International prospective register of systematic reviews (2013)
Plasmodium vivax infection on severe malaria in children: a meta-analysis.
CRD42013006952
23. Abdallah TM, Abdeen MT, Ahmed IS, Hamdan HZ, Magzoub M, Adam I
(2013) Severe Plasmodium falciparum and Plasmodium vivax malaria among
adults at Kassala hospital, eastern Sudan. Malar J. 12:148.
24. Alexandre MA, Ferreira CO, Siqueira AM, Magalhaes BL, Mourao MP, et al
(2010) Severe Plasmodium vivax malaria, Brazilian Amazon. Emerg Infect Dis
16:1611–1614.
25. Barber BE, William T, Grigg MJ, Menon J, Auburn S, et al (2009) A prospective
comparative study of knowlesi, falciparum, and vivax malaria in Sabah,
Malaysia: high proportion with severe disease from Plasmodium knowlesi and
Plasmodium vivax but no mortality with early referral and artesunate therapy.
Clin Infect Dis 56:383–397.
26. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti, et al (2007)
Demographic risk factors for severe and fatal vivax and falciparum malaria
among hospital admissions in northeastern Indonesian Papua. Am J Trop Med
Hyg 77:984–991.
27. Douglas NM, Lampah DA, Kenangalem E, Simpson JA, Poespoprodjo JR, et al
(2013) Major burden of severe anemia from non-falciparum malaria species in
Southern Papua: a hospital-based surveillance study. PLoS Med 10:e1001575.
28. Gehlawat VK, Arya V, Kaushik JS, Gathwala G (2013) Clinical spectrum and
treatment outcome of severe malaria caused by Plasmodium vivax in 18 children
from northern India. Pathog Glob Health 107:210–214.
29. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, et al (2008) Plasmodium
vivax and mixed infections are associated with severe malaria in children: a
prospective cohort study from Papua New Guinea. PLoS Med 5:e127.
30. Haroon H, Fazel PA, Naeem M, Mobin A, Naqvi AH, Makki K (2013) Hide
and seek: hematological aspects of malaria - a developing country perspective.
J Infect Dev Ctries 7:273–279.
31. Jain V, Agrawal A, Singh N (2013) Malaria in a tertiary health care facility of
Central India with special reference to severe vivax: implications for malaria
control. Pathog Glob Health 107:299–304.
32. Kaushik JS, Gomber S, Dewan P (2012) Clinical and epidemiological profiles of
severe malaria in children from Delhi, India. J Health Popul Nutr 30:113–116.
33. Ketema T, Bacha K (2013) Plasmodium vivax associated severe malaria
complications among children in some malaria endemic areas of Ethiopia. BMC
Public Health 13:637.
34. Kochar DK, Tanwar GS, Khatri PC, Kochar SK, Sengar GS, et al (2010)
Clinical features of children hospitalized with malaria–a study from Bikaner,
northwest India. Am J Trop Med Hyg 83:981–989.
35. Kochar DK, Das A, Kochar A, Middha S, Acharya J, et al (2010)
Thrombocytopenia in Plasmodium falciparum, Plasmodium vivax and mixed
infection malaria: a study from Bikaner (Northwestern India). Platelets 21:623–
627.
36. Lanca EF, Magalhaes BM, Vitor-Silva S, Siqueira AM, Benzecry SG, et al
(2012) Risk factors and characterization of Plasmodium vivax associated
admissions to pediatric intensive care units in the Brazilian Amazon. PLoS
One 7:e35406.
37. Limaye CS, Londhey VA, Nabar ST (2012) The study of complications of vivax
malaria in comparison with falciparum malaria in Mumbai. J Assoc Physicians
India. 60:15–18.
38. Manning L, Laman M, Law I, Bona C, Aipit S, et al (2011) Features and
prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium
vivax and mixed Plasmodium species in Papua New Guinean children. PLoS
One 6:e29203.
39. Manning L, Laman M, Rosanas-Urgell A, Michon P, Aipit S, et al (2012) Severe
anemia in Papua New Guinean children from a malaria-endemic area: a case-
control etiologic study. PLoS Negl Trop Dis 6:e1972.
40. Nurleila S, Syafruddin D, Elyazar IR, Baird JK (2012) Serious and fatal illness
associated with falciparum and vivax malaria among patients admitted to
hospital at West Sumba in eastern Indonesia. Am J Trop Med Hyg 87:41–49.
41. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Hasanuddin A, et al
(2009) Vivax malaria: a major cause of morbidity in early infancy. Clin Infect
Dis 48:1704–1712.
Severe Vivax Malaria: Systematic Review and Meta-Analysis
PLOS Neglected Tropical Diseases | www.plosntds.org 10 August 2014 | Volume 8 | Issue 8 | e3071
42. Rizvi I, Tripathi DK, Chughtai AM, Beg M, Zaman S, et al (2013)
Complications associated with Plasmodium vivax malaria: a retrospective study
from a tertiary care hospital based in Western Uttar Pradesh, India. Ann Afr
Med 12:155–159.
43. Shaikh S, Memon H, Iohano B, Shaikh A, Ahmed I, et al (2012) Severe disease
in children hospitalized with a diagnosis of Plasmodium vivax in south-eastern
Pakistan. Malar J 11:144.
44. Sharma R, Gohain S, Chandra J, Kumar V, Chopra A, et al (2012) Plasmodium
vivax malaria admissions and risk of mortality in a tertiary-care children’s
hospital in North India. Paediatr Int Child Health 32:152–157.
45. Singh R, Kumar S, Rana SK, Thakur B, Singh SP (2013) A comparative study
of clinical profiles of vivax and falciparum malaria in children at a tertiary care
centre in uttarakhand. J Clin Diagn Res 7:2234–2237.
46. Zubairi AB, Nizami S, Raza A, Mehraj V, Rasheed AF, et al (2013) Severe
Plasmodium vivax malaria in Pakistan. Emerg Infect Dis 19:1851–1854.
47. Tanwar GS, Khatri PC, Sengar GS, Kochar A, Kochar SK, et al (2011) Clinical
profiles of 13 children with Plasmodium vivax cerebral malaria. Ann Trop
Paediatr 31:351–356.
48. Rosanas-Urgell A, Lin E, Manning L, Rarau P, Laman M, et al (2012) Reduced
risk of Plasmodium vivax malaria in Papua New Guinean children with
Southeast Asian ovalocytosis in two cohorts and a case-control study. PLoS Med
9:e1001305.
49. Raposo CC, Santos JB, Santos GM, Gonc¸alves Eda G, Silva AR, et al (2013)
Plasmodium vivax malaria: related factors to severity in the State of Maranhao,
Brazil. Rev Soc Bras Med Trop 46:67–72.
50. Sharma S, Aggarwal KC, Deswal S, Raut D, Roy N, et al (2013) The unusual
presentation of a usual organism - the changing spectrum of the clinical
manifestations of Plasmodium vivax malaria in children: a retrospective study.
J Clin Diagn Res7:1964–1947.
51. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, et al (2007) The risk of
malarial infections and disease in Papua New Guinean children. Am J Trop
Med Hyg 76: 997–1008.
52. Khaireh BA, Briolant S, Pascual A, Mokrane M, Machault V, et al (2012)
Plasmodium vivax and Plasmodium falciparum infections in the Republic of
Djibouti: evaluation of their prevalence and potential determinants. Malar J
11:395.
53. Leal-Santos FA, Silva SB, Crepaldi NP, Nery AF, Martin TO, et al (2013)
Altered platelet indices as potential markers of severe and complicated malaria
caused by Plasmodium vivax: a cross-sectional descriptive study. Malar J 12:462.
54. Kwak YG, Lee HK, Kim M, Um TH, Cho CR (2013) Clinical characteristics of
vivax malaria and analysis of recurred patients. Infect Chemother 45:69–75.
55. Safeukui-Noubissi I, Ranque S, Poudiougou B, Keita M, Traore A, et al (2004)
Risk factors for severe malaria in Bamako, Mali: a matched case-control study.
Microbes Infect 6:572–578.
56. Lacerda MV, Mourao MP, Alexandre MA, Siqueira AM, Magalhaes BM, et al
(2012) Understanding the clinical spectrum of complicated Plasmodium vivax
malaria: a systematic review on the contributions of the Brazilian literature.
Malar J 11:12.
57. Cullen KA, Arguin PM; Division of parasitic diseases and malaria, Center for
Global Health, Centers for Disease Control and Prevention (CDC) (2013)
Malaria surveillance–United States, 2011. MMWR Surveill Summ. 62:1–17.
58. Nicol WD (1933) The relation of syphilis to mental disorder and the treatment of
G.P.I. by malaria. Br J Vener Dis 9:219–229.
59. Baird JK (2007) Neglect of Plasmodium vivax malaria. Trends Parasitol 23:533–
539.
60. Lacerda MV, Fragoso SC, Alecrim MG, Alexandre MA, Magalhaes BM, et al
(2012) Postmortem characterization of patients with clinical diagnosis of
Plasmodium vivax malaria: to what extent does this parasite kill? Clin Infect
Dis 55:e67–74.
61. Mueller I, Kaiok J, Reeder JC, Cortes A (2002) The population structure of
Plasmodium falciparum and Plasmodium vivax during an epidemic of malaria in
the eastern highlands of Papua New Guinea. Am J Trop Med Hyg 67: 459–464.
62. Collins WE, Jeffery GM, Roberts JM (2003) A retrospective examination of
anemia during infection of humans with Plasmodium vivax. Am J Trop Med
Hyg 68:410–41263.
63. Handayani S, Chiu DT, Tjitra E, Kuo JS, Lampah D, et al. High deformability
of Plasmodium vivax-infected red blood cells under microfluidic conditions.
J Infect Dis 2009 199:445–450.
64. Parakh A, Agarwal N, Aggarwal A, Aneja A (2009) Plasmodium vivax malaria in
children: uncommon manifestations. Ann Trop Paediatr 29:253–256.
65. Anstey NM, Russell B, Yeo TW, Price RN (2009) The pathophysiology of vivax
malaria. Trends Parasitol 25:220–227.
66. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, et al (2007) Lung
injury in vivax malaria: pathophysiological evidence for pulmonary vascular
sequestration and post-treatment alveolar-capillary inflammation. J Infect Dis
195:589–596.
67. Cunnington AJ, Riley EM, Walther M (2013) Stuck in a rut? Reconsidering the
role of parasite sequestration in severe malaria syndromes. Trends Parasitol
29:585–592.
68. Baird JK (2004) Minireview: Chloroquine resistance in Plasmodium vivax.
Antimicrob Agents chemother 48: 4075–4083.
69. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, et al (2008)
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax.
J Infect Dis 198:1558–1564.
70. Kling PJ, Schmidt RL, Roberts RA, Widness JA (1996) Serum erythropoietin
levels during infancy: associations with erythropoiesis. J Pediatr 128:791–796.
Severe Vivax Malaria: Systematic Review and Meta-Analysis
PLOS Neglected Tropical Diseases | www.plosntds.org 11 August 2014 | Volume 8 | Issue 8 | e3071
